Európai Unió - bolgár - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - адалимумаб - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - Имуносупресори - Моля, направете справка в раздел 4. 1 от Кратката характеристика на продукта в документа с информация за продукта.

Bulgária - bolgár - Изпълнителна агенция по лекарствата

pharmacosmos a/s - Комплекс железен оксид декстран - 50 mg/ml solution for injection/infusion

Bulgária - bolgár - Изпълнителна агенция по лекарствата

pharmacosmos a/s - Комплекс железен оксид декстран - 100 mg/ml solution for injection/infusion

Bulgária - bolgár - Изпълнителна агенция по лекарствата

vifor france sa - Желязо азотен полимальтозный комплекс - 10 mg/ml syrup

Bulgária - bolgár - Изпълнителна агенция по лекарствата

pharmacosmos a/s - Комплекс железен оксид декстран - 50 mg/ml solution for injection

Európai Unió - bolgár - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Антинеопластични средства - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Bulgária - bolgár - БАБХ (Българска агенция по безопасност на храните)

merial - Желязо (като комплекс декстран) - инжекционен разтвор - 20.0 g/100 ml - прасета

Bulgária - bolgár - БАБХ (Българска агенция по безопасност на храните)

pharmacosmos - Желязо (iii) хидроксид декстрана комплекс - инжекционен разтвор - 200 mg/ml - прасета

Európai Unió - bolgár - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - Неоплазми на гърдата - Антинеопластични средства - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Európai Unió - bolgár - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - Антинеопластични средства - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.